OncLive TV

Carla Falkson, MBChB, MMed, MD, discusses the potential to de-escalate chemotherapy in HER2-positive breast cancer.

Deborah M. Stephens, DO, discusses the phase 3 ELEVATE-RR trial comparing the safety and efficacy of acalabrutinib with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Evan Y. Yu, MD, discusses the utility of enfortumab vedotin-ejfv in patients with locally advanced or metastatic urothelial cancer. 

Petros Grivas, MD, PhD, discusses attempts to improve upon chemotherapy as a therapeutic strategy in urothelial cancer.

Ami P. Vaidya, MD, discusses advances in the management of endometrial cancer.

Jeff Michalski, MD, MBA, FASTRO, discusses the goals of the American Society for Radiation Oncology in radiation oncology.

Nathaniel Ivanick, MD, FCCP, discusses the role of interventional pulmonologists in advanced diagnostics in lung cancer.

Mothaffar Fahed Rimawi, MD, discusses future research directions in metastatic HER2-positive breast cancer. 

Sarah Elizabeth Yentz, MD, discusses unmet needs in metastatic renal cell carcinoma.

Phillip Palmbos, MD, PhD, discusses the role of chemoimmunotherapy in patients with bladder cancer.

Heloisa P. Soares, MD, PhD, discusses the standard of care in metastatic pancreatic cancer.

Corey J. Langer, MD, discusses the need for reflex testing in patients with non–small cell lung cancer.

Glenn J. Hanna, MD, discusses promising data reported with tipifarnib in patients with HRAS-mutated head and neck cancer.

John F. Lazar, MD, discusses risk stratification for chemotherapy and adjuvant therapy in lung cancer.

Rodolfo Bordoni, MD, discusses the utility of ​adjuvant osimertinib in lung cancer.

Wasif M. Saif, MD, MBBS, discusses the rationale to utilize PARP inhibitors in BRCA-mutated pancreatic cancer.

Terri Parker, MD, discusses considerations to optimize treatment in multiple myeloma.

Gretchen G. Kimmick, MD, MS, discusses the results of the phase 2 ATEMPT trial in early-stage HER2-positive breast cancer

Deborah M. Stephens, DO, director of the CLL and Lymphoma Program, Huntsman Cancer Institute, discusses optimizing treatment selection in chronic lymphocytic leukemia.

Sarbajit Mukherjee, MD, MS, discusses considerations to inform when to initiate immunotherapy in gastroesophageal cancer.

Sarah Sammons, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

John L. Marshall, MD, discusses the potential utility of trastuzumab deruxtecan in HER2-positive gastric cancer.

Anthony Mato, MD, MSCE, discusses the potential utilization of CAR T-cell therapy in earlier lines of therapy in chronic lymphocytic leukemia.

Francisco Javier Esteva, MD, PhD, discusses the clinical implications of the fixed-dose regimen comprised of subcutaneous trastuzumab and pertuzumab in the treatment of patients with HER2-positive breast cancer.

Bilal A. Siddiqui, MD, discusses the potential for novel imaging in patients with nonmetastatic castration-resistant prostate cancer.

Ashish Saxena, MD, PhD, discusses a challenging case of a patient with non–small cell lung cancer.

Marjorie G. Zauderer, MD, discusses the importance of optimizing care for patients with mesothelioma.

Julie Renee Brahmer, MD, MSc, discusses questions regarding the role of consolidative immunotherapy vs targeted therapy in locally advanced non–small cell lung cancer.

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the next steps to improve outcomes for patients with lung cancer.

Nathaniel Ivanick, MD, FCCP, discusses advancements in interventional pulmonology.